Table 1.
Target | Sequence (5′ to 3′) | bp | R2 | Eff. (%) | Accession | Reference | |
---|---|---|---|---|---|---|---|
β-Actin | F R |
GCTACAGCTTCACCACCACA TCTCCAGGGAGGAAGAGGAT |
123 | 1.000 | 102.0 | XM_006998174.2 | [37] |
Oas1b | F R |
CAGTATGCCCTGGAGCTGC GTACTTGGTGACCAGTTCC |
111 | 0.998 | 98.3 | XM_006970848.1 | This study |
Ifng | F R |
ACAGCAGTGAGGAGAAACGG GACAGGCGGTACATCACTCC |
115 | 0.970 | 94.7 | AY289494.1 | This study |
Tnf | F R |
GGGCTGTACCTCGTCTACTC ACAGGAGGTTGACTTTGTCC |
121 | 0.999 | 100.4 | XM_006995235.2 | This study |
Tgfb | F R |
CGTGGAACTCTACCAGAAATACAGC TCAAAAGACAACCACTCAGGCG |
96 | 0.999 | 95.6 | XM_006988036.2 | [38] |
IL6 | F R |
CCATCCAACTCATCCTGAAAGC CCACAGATTGGTACACATAGGCAC |
101 | 0.999 | 96.1 | AY256518.1 | [38] |
IL10 | F R |
CAGACCTACACGCTTCGAG CCCAGGTAACCCTTAAAGTCC |
128 | 0.999 | 111.2 | XM_006995328.2 | This study |
MODV-NS5 | F R |
CCAGGACAAGTCATGTGGTAGC TCCCAAAGATGTTCCTCACCTT |
101 | 0.998 | 107.5 | NC_003635.1 | [39] |